Latest 30 News in the Life Sciences Industry
GlobeNewswire
European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU
17 Jul 2026
PR Newswire Association LLC.
Medtronic and Apollo Hospitals Announce Strategic Partnership to Establish State-of-the-Art Advanced ICU in Hyderabad
17 Jul 2026
PR Newswire Association LLC.
Creative Life Science Advances PIC/S GMP-Compliant Cell Therapy Materials and Manufacturing Platform
17 Jul 2026
GlobeNewswire
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
17 Jul 2026
GlobeNewswire
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
16 Jul 2026
GlobeNewswire
InnoCare Announces Phase II Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint in Patients with Vitiligo
16 Jul 2026
GlobeNewswire
Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio
16 Jul 2026
GlobeNewswire
Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
16 Jul 2026
GlobeNewswire
Novo Nordisk receives European Commission approval of Wegovy® pill as first oral GLP-1 for weight management in the EU; single, ready-to-use pen for higher dose 7.2 mg also approved
15 Jul 2026
GlobeNewswire
Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.
15 Jul 2026
GlobeNewswire
InnoCare Announces Phase III Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint in Patients with Atomic Dermatitis
15 Jul 2026
GlobeNewswire
InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL
14 Jul 2026
PR Newswire Association LLC.
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
14 Jul 2026
PR Newswire Association LLC.
Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB
13 Jul 2026
GlobeNewswire
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
13 Jul 2026
GlobeNewswire
Study Results of Orelabrutinib in Patients with SLE Published in the Journal of Autoimmunity
10 Jul 2026
PR Newswire Association LLC.
Wegovy® (semaglutide) label updated in Singapore with higher dose supported by STEP UP evidence
08 Jul 2026
PR Newswire Association LLC.
Altruist Biologics' Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval for Segmented Production
08 Jul 2026
PR Newswire Association LLC.
Ascletis Submits Two IND Applications to U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35
06 Jul 2026
PR Newswire Association LLC.
Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist A
06 Jul 2026
PR Newswire Association LLC.
Everest Medicines Announces China NMPA Acceptance of the Biologics License Application for LEROCHOL® in Adults with Hypercholesterolemia
26 Jun 2026
PR Newswire Association LLC.
Haier Biomedical Debuts Innovative Automated Low-Carbon Cold Storage Products at Two Major Global Industry Trade Fairs
25 Jun 2026
PR Newswire Association LLC.
C-Ray Therapeutics Receives Radiopharmaceutical Manufacturing Authorization under China's MAH Framework
25 Jun 2026
PR Newswire Association LLC.
CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand
25 Jun 2026
PR Newswire Association LLC.
WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
24 Jun 2026
Upcoming Events All Events
- July 2026
- Taipei: BIO Asia-Taiwan
- August 2026
- Online: Biotechgate Digital Partnering August 2026
- September 2026
- Marina Bay Sands: Asia Bio Partnering Forum